North China Pharmaceutical Group Co., LTD. (hereinafter referred to as Huapao Group) is located in Shijiazhuang, the capital city of Hebei Province. The predecessor, North China Pharmaceutical Factory, was a key construction project during China's "First Five" plan, which began to build in June 1953 and was completed and put into operation in June 1958, creating a history of large-scale production of antibiotics in China, and making important contributions to the cause of human health, the development of national pharmaceutical industry and the change of the situation of lack of medicine in China. In 1994, it was listed in Shanghai Stock Exchange (stock name: North China Pharmaceutical 600812). Over the years, Huapao Group adhering to the "human health first, quality always first" business purpose, continuous innovation, steady management, gradually growing, business scope continues to expand, development performance maintained excellent, the main economic and technical indicators have always been in the forefront of the domestic industry. By the end of 2018, the total assets of Huafu Group were 20.6 billion yuan, nearly 15,000 employees, more than 40 subsidiaries (sub-companies), and three national innovation platforms: National Engineering Research Center for microbial drugs, State Key Laboratory for Antibody drug Development, and National and local joint Engineering Laboratory for Antibiotic enzyme Catalysis and Crystallization Technology. The main products involve nearly a thousand product specifications in the fields of chemical pharmaceutical, modern biotechnology drugs, vitamins and nutritional health products, modern Chinese medicine, biological agriculture and veterinary drugs, and the treatment field covers anti-infection, cardiovascular and cerebrovascular, kidney disease, anti-tumor and immune regulation, etc. The process route and production layout of the main production units are all designed and implemented in accordance with the current European and American versions and the new Chinese GMP standards. It has a modern pharmaceutical production platform with international leading standards.